Beam Therapeutics BEAM Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Beam Therapeutics’s reported figures.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's free cash flow?
- Beam Therapeutics (BEAM) reported free cash flow of -$130.75M in Q1 2026.
- How has Beam Therapeutics's free cash flow changed year-over-year?
- Beam Therapeutics's free cash flow decreased by 22.2% year-over-year, from -$106.95M to -$130.75M.
- What is the long-term trend for Beam Therapeutics's free cash flow?
- Over 2 years (2021 to 2025), Beam Therapeutics's free cash flow has grown at a 78.4% compound annual growth rate (CAGR), from -$113.08M to -$360.05M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.